- Home
- IROH vs CHRS Comparison
IROH vs CHRS Comparison
Compare IROH & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROH
- CHRS
- Stock Information
- Founded
- IROH 2021
- CHRS 2010
- Country
- IROH United States
- CHRS United States
- Employees
- IROH N/A
- CHRS N/A
- Industry
- IROH
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IROH
- CHRS Health Care
- Exchange
- IROH Nasdaq
- CHRS Nasdaq
- Market Cap
- IROH 90.7M
- CHRS 100.9M
- IPO Year
- IROH 2023
- CHRS 2014
- Fundamental
- Price
- IROH $10.28
- CHRS $0.77
- Analyst Decision
- IROH
- CHRS Strong Buy
- Analyst Count
- IROH 0
- CHRS 4
- Target Price
- IROH N/A
- CHRS $6.13
- AVG Volume (30 Days)
- IROH 7.5K
- CHRS 2.6M
- Earning Date
- IROH 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- IROH N/A
- CHRS N/A
- EPS Growth
- IROH N/A
- CHRS N/A
- EPS
- IROH 0.72
- CHRS N/A
- Revenue
- IROH N/A
- CHRS $304,340,000.00
- Revenue This Year
- IROH N/A
- CHRS $3.33
- Revenue Next Year
- IROH N/A
- CHRS $16.77
- P/E Ratio
- IROH $14.30
- CHRS N/A
- Revenue Growth
- IROH N/A
- CHRS 44.19
- 52 Week Low
- IROH $9.97
- CHRS $0.66
- 52 Week High
- IROH $11.11
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- IROH N/A
- CHRS 42.38
- Support Level
- IROH N/A
- CHRS $0.77
- Resistance Level
- IROH N/A
- CHRS $0.89
- Average True Range (ATR)
- IROH 0.00
- CHRS 0.08
- MACD
- IROH 0.00
- CHRS 0.02
- Stochastic Oscillator
- IROH 0.00
- CHRS 38.17
About IROH Iron Horse Acquisitions Corp. Common Stock
Iron Horse Acquisitions Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.